Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 4/20 | 0.60 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 8/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 4/20 | 0.42 |
| ▸ | FLT1 | P17948 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | BLK | P51451 | 3/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877293 | 0.93 | MAP2 (0.63) | MAP2HPSEKDRPDGFRBFLT3 | |
| SCHEMBL1880344 | 0.91 | MAP2 (0.59) | MAP2KDRPDGFRBCSF1RFLT1 | |
| SCHEMBL1881945 | 0.89 | MAP2 (0.58) | MAP2HPSEKDRPDGFRBCSF1R | |
| SCHEMBL1882722 | 0.87 | MAP2 (0.54) | MAP2HPSEKDRPDGFRBCSF1R | |
| SCHEMBL1881761 | 0.87 | MAP2 (0.56) | MAP2HPSEROCK2MEN1KMT2A | |
| SCHEMBL1880392 | 0.86 | MAP2 (0.63) | MAP2HPSEKDRFLT3KIT | |
| SCHEMBL4075062 | 0.86 | MAP2 (0.63) | MAP2HPSEMEN1KMT2A | |
| SCHEMBL1888564 | 0.86 | KDR (0.58) | MAP2KDRPDGFRBCSF1RFLT1 | |
| SCHEMBL1881221 | 0.85 | MAP2 (0.60) | MAP2HPSEKDRKITROCK2 | |
| Trifluoroacetic Acid SCHEMBL1883581 | 0.85 | MAP2 (0.55) | MAP2KDRPDGFRBCSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | claimed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | claimed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | claimed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | claimed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | claimed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | disclosed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | WEE1, CNKSR1, WEE2 | MAP2 1477/4885HPSE 4869/4885KDR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.